Article Text

Download PDFPDF

278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer
  1. George Blumenschein1,
  2. Siddhartha Devarakonda2,
  3. Melissa Johnson3,
  4. Victor Moreno4,
  5. Justin Gainor5,
  6. Martin Edelman6,
  7. John Heymach1,
  8. Ramaswamy Govindan2,
  9. Carlos Bachier7,
  10. Bernard Doger de Spéville4,
  11. Matthew Frigault5,
  12. Anthony Olszanski6,
  13. Vincent Lam1,
  14. Natalie Hyland8,
  15. Jean-Marc Navenot8,
  16. Svetlana Fayngerts8,
  17. Jane Bai8,
  18. Elliot Norry8 and
  19. Paula Fracasso8
  1. 1MD Anderson Cancer Center, Houston, TX, USA
  2. 2Washington University School of Medicine, Saint Louis, MO, USA
  3. 3Sarah Cannon Research Institute, Nashville, TN, USA
  4. 4Fundación Jiménez Díaz Univ. Hospital, Madrid, Spain
  5. 5Massachusetts General Hospital, Boston, MA, USA
  6. 6Fox Chase Cancer Center, Philadelphia, PA, USA
  7. 7Sarah Cannon Center for Blood Cancer, Nashville, TN, USA
  8. 8Adaptimmune, Abingdon, UK


Background ADP-A2M10 SPEAR T-cells are genetically engineered autologous T-cells that express a high affinity MAGE-A10-specific T-cell receptor targeting MAGE-A10+tumors in the context of HLA-A*02. This trial is now complete (NCT02592577).

Methods This first-in-human dose escalation trial utilized a modified 3+3 design to evaluate safety and antitumor activity. Eligible patients (pts) were HLA-A*02+ with advanced non-small cell lung cancer (NSCLC) expressing MAGE-A10. Pts underwent apheresis; T-cells were isolated, transduced with a lentiviral vector containing the TCR targeting MAGE-A10, and expanded. Pts underwent lymphodepletion (LD) with varying doses/schedules of fludarabine (Flu) and cyclophosphamide (Cy) prior to receiving ADP-A2M10. ADP-A2M10 was administered at Dose Level (DL) 1= 0.1×109, DL2 0.5–1.2×109, and DL3/Expansion= 1.2–15×109 transduced cells.

Results As of Jan 10, 2020, 11 pts (6 male/5 female) with NSCLC (3 squamous cell, 7 adenocarcinoma, 1 adenosquamous) were treated. Five, 3 and 3 pts received cells at DL1, DL2, and DL3/Expansion, respectively. The most frequently reported adverse events ≥ Grade 3 were lymphopenia (11), leukopenia (9), neutropenia (8), anemia (6), thrombocytopenia (5), and hyponatremia (5). Three pts reported CRS (Grades 1, 2, and 4, respectively). One pt received the highest dose of LD (Flu 30 mg/m2 Day 1 4 and Cy 1800 mg/m2 Day 1–2) prior to a second infusion and had a partial response (PR). This pt subsequently developed aplastic anemia and died. Responses included: 1 pt – PR, 3 pts - stable disease, 2 pts – progressive disease, 1 pt - too early to determine, 4 pts - off-study prior to tumor assessment. SPEAR T-cells were detectable in peripheral blood from pts at each dose level, and in tumor tissue from pts at DL1 and DL3.

Conclusions ADP-A2M10 SPEAR T-cells have shown acceptable safety and no evidence of toxicity related to off-target binding or alloreactivity. Given the minimal antitumor activity and the discovery that MAGE-A10 expression frequently overlaps with MAGE-A4 expression, the clinical program has closed. Several trials with SPEAR T-cells targeting MAGE-A4 are ongoing (

Trial Registration NCT02592577

Ethics Approval The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines and was approved by local authorities. An independent ethics committee or institutional review board approved the clinical protocol at each participating center. All the patients provided written informed consent before study entry.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.